Cabaletta Bio is a clinical-stage biotechnology company focused on developing T cell therapies with potential to provide durable, perhaps curative, treatment for patients with autoimmune diseases. CABA-201, a CD19-CAR T cell therapy, is being evaluated in the RESET™ Phase 1/2 trials across several autoimmune diseases, including adult and juvenile myositis. Tania Gonzalez Rivera, M.D., discusses the application of CAR-T cell […]